Advaxis’ Experimental Cancer Immunotherapy Axalimogene Filolisbac Boosts Survival Rates In Cervical Cancer Patients Advaxis Inc.'s new experimental vaccine was tested by a separate group and was found to prolong metastatic cervical cancer patients' lifespans by one year. by Julienne Roman